Strides Arcolab's arm starts construction of new facility in Malaysia

04 Dec 2014 Evaluate

Stelis Biopharma, a wholly owned subsidiary of Strides Arcolab, has started the construction of its customized, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia. The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park.

The 140,000 square foot facility will incorporate ‘next-gen’ single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few Regulated Market approvable facilities in the Region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

896.80 -1.20 (-0.13%)
03-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.40
Dr. Reddys Lab 6332.85
Cipla 1424.40
Zydus Lifesciences 992.00
Lupin 1663.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.